[go: up one dir, main page]

AR022427A1 - Cetonas peptidil heterociclicas utiles como inhibidoras de la triptasa - Google Patents

Cetonas peptidil heterociclicas utiles como inhibidoras de la triptasa

Info

Publication number
AR022427A1
AR022427A1 ARP000100333A ARP000100333A AR022427A1 AR 022427 A1 AR022427 A1 AR 022427A1 AR P000100333 A ARP000100333 A AR P000100333A AR P000100333 A ARP000100333 A AR P000100333A AR 022427 A1 AR022427 A1 AR 022427A1
Authority
AR
Argentina
Prior art keywords
inhibitors
ketones
heterociclicas
peptidil
triptase
Prior art date
Application number
ARP000100333A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of AR022427A1 publication Critical patent/AR022427A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a una serie de quetonas heterocíclicas de peptidilo que son inhibidores de la proteasa serina de la célula inflamatoria ysus composiciones y losmétodos para la prevencion y el tratamiento de una variedad de desordenes inflamatorios inmunomediados. Más particularmente, estos compuestos son inhibidorespotentes y selectivos de la triptasa y son por lo tanto efectivos para la prevencion y el tratamiento de las enfermedades inflamatorias asociadas con el tractorespiratorio tal como el asmay la rinitis alérgica.
ARP000100333A 1999-01-27 2000-01-26 Cetonas peptidil heterociclicas utiles como inhibidoras de la triptasa AR022427A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11760299P 1999-01-27 1999-01-27

Publications (1)

Publication Number Publication Date
AR022427A1 true AR022427A1 (es) 2002-09-04

Family

ID=22373811

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100333A AR022427A1 (es) 1999-01-27 2000-01-26 Cetonas peptidil heterociclicas utiles como inhibidoras de la triptasa

Country Status (24)

Country Link
US (2) US6469036B1 (es)
EP (1) EP1147097A1 (es)
JP (1) JP2002535394A (es)
KR (1) KR20010110422A (es)
CN (1) CN1353701A (es)
AR (1) AR022427A1 (es)
AU (1) AU3208500A (es)
BG (1) BG105762A (es)
BR (1) BR0007778A (es)
CA (1) CA2361479A1 (es)
CZ (1) CZ20012722A3 (es)
EA (1) EA200100815A1 (es)
EE (1) EE200100391A (es)
HK (1) HK1038561A1 (es)
HR (1) HRP20010601A2 (es)
HU (1) HUP0201295A3 (es)
IL (1) IL144577A0 (es)
NO (1) NO20013666L (es)
SK (1) SK10742001A3 (es)
TR (1) TR200102766T2 (es)
TW (1) TWI229669B (es)
WO (1) WO2000044733A1 (es)
YU (1) YU61401A (es)
ZA (1) ZA200106995B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
EE200200555A (et) * 2000-03-27 2004-06-15 Applied Research Systems Ars Holding N.V. Farmatseutiliselt aktiivsed pürrolidiini derivaadid
WO2001074769A1 (en) * 2000-03-27 2001-10-11 Applied Research Systems Ars Holding N.V. Pharmaceutically active pyrrolidine derivatives as bax inhibitors
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US6797461B2 (en) * 2000-10-27 2004-09-28 Promega Corporation Tryptase substrates and assay for tryptase activity using same
WO2002055073A1 (en) * 2001-01-05 2002-07-18 Kyowa Kakko Kogyo Co., Ltd. Preventives for arthritis
EP1358178A2 (en) 2001-01-30 2003-11-05 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
GB0103765D0 (en) * 2001-02-15 2001-04-04 Affitech As Assay
US20060183664A1 (en) * 2001-12-13 2006-08-17 Toshiaki Takizawa Pharmaceutical composition for delayed hypersensitivity
AU2003237224A1 (en) * 2002-05-29 2003-12-19 Merck And Co., Inc. 1,2 diamido cycloalkyl sodium channel blockers
DE10249304B4 (de) * 2002-10-22 2006-09-28 Cytec Surface Specialties Germany Gmbh & Co. Kg Wäßrige Beschichtungsmittel
US7205384B2 (en) * 2003-08-05 2007-04-17 Ortho-Mcneil Pharmaceutical Inc. Process for preparing peptidyl heterocyclic ketone derivatives
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
CA2555227A1 (en) * 2004-02-10 2005-08-25 Janssen Pharmaceutica, N.V. Pyridazinone ureas as antagonists of .alpha.4 integrins
CA2576971A1 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
KR101069051B1 (ko) * 2006-05-23 2011-09-29 아이알엠 엘엘씨 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
CA2651043A1 (en) * 2006-05-23 2007-12-06 David C. Tully Compounds and compositions as channel activating protease inhibitors
AU2008214214B2 (en) * 2007-02-09 2011-09-15 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2117537A1 (en) * 2007-02-09 2009-11-18 Irm Llc Compounds and compositions as channel activating protease inhibitors
KR101131238B1 (ko) 2007-02-09 2012-03-30 아이알엠 엘엘씨 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
ES2351323B1 (es) * 2009-06-26 2011-10-05 Institut Univ. De Ciència I Tecnologia, S.A. Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para el descubrimiento de farmacos.
EP2714716B1 (en) 2011-06-02 2018-04-11 Socpra Sciences Santé Et Humaines S.E.C. Matriptase inhibitors and uses thereof against orthomyxoviridae infections
CN103145598B (zh) * 2011-12-07 2014-10-15 北京京卫顺康医药科技发展有限公司 一种奥沙西罗晶体及含有该晶体的组合物
SMT201800411T1 (it) * 2013-10-29 2018-09-13 Biomarin Pharm Inc Derivati di n-(1-idrossi-3-(pirrodinil) propan-2-il) pirrolidina-3-carbossammide come inibitori di glucosilceramide sintasi
AU2015328385B2 (en) * 2014-10-06 2020-06-11 Lighthouse Pharmaceuticals, Inc. Inhibitors of lysine gingipain
WO2016144654A1 (en) * 2015-03-09 2016-09-15 Washington University Inhibitors of growth factor activation enzymes
CA3004095A1 (en) 2015-11-09 2017-05-18 Cortexyme, Inc. Inhibitors of arginine gingipain
JP7113815B2 (ja) 2016-09-16 2022-08-05 コーテクシーミー， インコーポレイテッド リシンジンジパインのケトン阻害剤
JP7079794B2 (ja) 2017-05-10 2022-06-02 コーテクシーミー， インコーポレイテッド アミノピリジン化合物ならびにその調製および使用のための方法
WO2023286844A1 (ja) * 2021-07-15 2023-01-19 国立研究開発法人国立国際医療研究センター 抗ウイルス活性等の生理活性を有する化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ263084A (en) 1993-03-12 1997-08-22 Arris Pharm Corp Dipeptide derivatives, treatment of immunomediated inflammatory disorders
JPH0820597A (ja) 1994-07-07 1996-01-23 Meiji Seika Kaisha Ltd トロンビン阻害作用を有する複素環カルボニル化合物
JPH10513151A (ja) 1994-12-22 1998-12-15 バイオケム ファーマ インコーポレイテッド トロンビン阻害剤としての複素環式ケトアルギニンペプチド
FI972466A7 (fi) 1994-12-22 1997-08-19 Iaf Biochem Int Pienen molekyylipainon bisyklisiä trombiini-inhibiittoreita
DE69615671T2 (de) 1995-03-24 2002-08-08 Molecumetics, Ltd. Beta-schleifenähnliche verbindungen und deren verwendung als protease-inhibitoren
WO1996030396A1 (en) 1995-03-24 1996-10-03 Molecumetics Ltd. β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS
GB9510264D0 (en) 1995-05-22 1995-07-19 Iaf Biochem Int Low molecular weight bicyclic-urea type thrombin inhibitors
US5827860A (en) * 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5827866A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5523308A (en) 1995-06-07 1996-06-04 Costanzo; Michael J. Peptidyl heterocycles useful in the treatment of thrombin related disorders
US6069130A (en) 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
IL119466A (en) 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
ATE320811T1 (de) 1996-08-05 2006-04-15 Myriad Genetics Inc Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors
AU4172397A (en) 1996-09-06 1998-03-26 Biochem Pharma Inc. Lactam inhibitors of thrombin
US5827886A (en) * 1997-05-07 1998-10-27 Thione International, Inc. Composition for relief of arthritis-induced symptoms
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
AU1176299A (en) 1997-11-26 1999-06-15 Yoshitomi Pharmaceutical Industries, Ltd. Tryptase inhibitors comprising heterocyclic amide compounds
AU1722099A (en) 1997-12-16 1999-07-05 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for regulating phagocytosis and icam-1 expression

Also Published As

Publication number Publication date
HUP0201295A3 (en) 2002-10-28
HK1038561A1 (zh) 2002-03-22
TWI229669B (en) 2005-03-21
US7132418B2 (en) 2006-11-07
NO20013666D0 (no) 2001-07-26
SK10742001A3 (sk) 2002-08-06
EA200100815A1 (ru) 2002-08-29
BR0007778A (pt) 2002-06-04
WO2000044733A1 (en) 2000-08-03
HRP20010601A2 (en) 2002-08-31
TR200102766T2 (tr) 2001-12-21
IL144577A0 (en) 2002-05-23
HUP0201295A2 (en) 2002-09-28
US20030008829A1 (en) 2003-01-09
BG105762A (en) 2002-03-29
CA2361479A1 (en) 2000-08-03
US6469036B1 (en) 2002-10-22
EP1147097A1 (en) 2001-10-24
JP2002535394A (ja) 2002-10-22
CN1353701A (zh) 2002-06-12
YU61401A (sh) 2005-07-19
AU3208500A (en) 2000-08-18
KR20010110422A (ko) 2001-12-13
NO20013666L (no) 2001-09-26
EE200100391A (et) 2002-10-15
ZA200106995B (en) 2002-11-25
CZ20012722A3 (cs) 2002-08-14

Similar Documents

Publication Publication Date Title
AR022427A1 (es) Cetonas peptidil heterociclicas utiles como inhibidoras de la triptasa
UY27774A1 (es) Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona
SV2004001414A (es) Inhibidores del factor xa y de otras proteasas de serina implicadas en la cascada de la coagulacion. pc20535
CR20120356A (es) Nuevos compuestos heterocíclicos activos como inhibidores de beta-lactamasas
ATE509917T1 (de) Gamma-secretase-inhibitoren
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE60325498D1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
ATE388708T1 (de) Piperazinderivate und anwendungsverfahren
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
SG151303A1 (en) New compounds for the inhibition of angiogenesis and use thereof
ECSP066717A (es) Compuestos de quinolina sustituidos
DE60239218D1 (de) Synergistische zusammensetzungen für die behandlung von saatgut
UY26889A1 (es) Compuestos farmacéuticos
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
ECSP055844A (es) Nuevos compuestos triciclicos
DE60220385D1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
ATE367380T1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
ATE443044T1 (de) Tace inhibitoren
ATE333872T1 (de) Zusammensetzng auf diclofenac-basis für die topische behandlung von erkrankungen des oropharynx
ATE380188T1 (de) Substituierte chinolone
UY29240A1 (es) Nuevos derivados de piridotienopirimidina
EA200500326A1 (ru) Применение ферментированного экстракта проростков пшеницы в качестве противовоспалительного агента
ATE410166T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit
ATE345135T1 (de) Tropan-derivate mit dopamin-wiederaufnahme-hemmer-wirkung für die behandlung von ischämischen erkrankungen
EA200800342A1 (ru) ИНГИБИТОРЫ Glepp-1 ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И/ИЛИ ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ

Legal Events

Date Code Title Description
FB Suspension of granting procedure